Humana Inc.

Report azionario NYSE:HUM

Capitalizzazione di mercato: US$43.4b

Humana Crescita futura

Criteri Future verificati 3/6

Humana prevede che gli utili e i ricavi cresceranno rispettivamente di 27% e 8.1% all'anno. Si prevede che l'EPS crescerà di 27.8% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 11.6% in 3 anni.

Informazioni chiave

27.0%

Tasso di crescita degli utili

27.83%

Tasso di crescita dell'EPS

Healthcare crescita degli utili19.4%
Tasso di crescita dei ricavi8.1%
Rendimento futuro del capitale proprio11.56%
Copertura analitica

Good

Ultimo aggiornamento24 Jun 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Articolo di analisi • Jun 16

Humana (HUM) Stock Could Be 78.6% Overvalued After Its Recent Rally

Humana (HUM) has drawn fresh attention after recent trading, with the stock showing a mix of short term gains and longer term declines that raises questions about how investors currently view its valuation. See our latest analysis for Humana. Recent trading has pushed Humana’s share price to $380.26, with a 30 day share price return of 24.63% and a 1 year total shareholder return of 64.10%. However, 3 and 5 year total shareholder returns remain in decline, suggesting momentum has recently...
Aggiornamento della narrazione • Jun 08

HUM: Medicare Advantage Rate And Stars Uncertainty Will Pressure Margins

Humana's updated analyst price target has moved higher from about $210 to roughly $290, as analysts point to muted medical cost trends, potential Medicare Advantage margin recovery, and company specific Stars improvement as key supports for earnings power. Analyst Commentary Recent research shows a clear reset higher in Humana's valuation framework, with multiple firms lifting price targets and, in some cases, upgrading ratings as they reassess earnings power tied to medical cost trends and Medicare Advantage margins.
Aggiornamento della narrazione • May 25

HUM: Medicare Advantage Margin Recovery Will Support Future Multiple Repricing

Humana's updated analyst price target of about $371, up from roughly $322, reflects analysts' focus on stabilizing managed care trends, expectations around Medicare Advantage margin recovery, and a shift to a slightly higher discount rate and profit margin in the underlying assumptions. Analyst Commentary Recent Street research on Humana centers on how quickly Medicare Advantage margins might stabilize, how medical loss ratios track against company targets, and what that could mean for valuation as managed care trends settle.
Seeking Alpha • May 18

Humana: Perhaps The 'Buy The Dip' Thesis Was Right All Along (Rating Upgrade)

Summary Humana Inc. is upgraded to Buy as shares rebound from a >65% decline, supported by improved CMS rate decisions and activist investor involvement. Despite 2026 EPS guidance below Q1 levels, HUM targets a sustainable 3%+ Medicare Advantage margin and long-term earnings growth by 2028. Recent Q1 results exceeded revenue and adjusted EPS expectations, with a favorable medical benefit ratio and affirmed 25% MA membership growth for 2026. Activist pressure and management’s focus on pricing, benefit adjustments, and operational discipline position HUM for a potential return to >$450/share by 2028. Read the full article on Seeking Alpha
Aggiornamento della narrazione • May 03

HUM: Medicare Advantage Margin Execution Will Support Future Multiple Repricing

Humana's updated fair value estimate has moved from $302.11 to $322.19 as analysts adjust price targets higher across multiple firms, citing recent research that reflects revised revenue growth, margin expectations, and a higher assumed future P/E of 14.99. Analyst Commentary Recent Street research around Humana has shifted from sharp cuts earlier in the year to a cluster of higher price targets more recently.
Aggiornamento della narrazione • Apr 19

HUM: Medicare Advantage Margin Recovery Will Offset Regulatory And Cost Uncertainty

Humana's updated analyst price target edges slightly lower to about $210, as analysts balance recent target cuts tied to Medicare Advantage margin concerns with more recent upward revisions that reflect adjusted models, a modestly lower discount rate, and a slightly different profit margin and forward P/E outlook. Analyst Commentary Recent Street research on Humana reflects a split view, with some analysts revising price targets higher after updating models, while others remain cautious following earlier target cuts and rating downgrades tied to Medicare Advantage margins and CMS rate decisions.
Aggiornamento della narrazione • Apr 04

HUM: Medicare Advantage Margin Recovery Will Drive Future Repricing Potential

Humana's updated analyst price target has shifted down from $348.00 to about $302.11, as analysts factor in lower target ranges across the Street, a higher discount rate, and cautious views on Medicare Advantage margins and earnings visibility. Analyst Commentary Recent Street research on Humana reflects a broadly cautious stance, with several firms cutting price targets and reassessing Medicare Advantage earnings power.
Aggiornamento della narrazione • Mar 21

HUM: Medicare Advantage Margin Recovery Will Offset Regulatory And Cost Headwinds

Humana's updated analyst price target has been trimmed by about $12 to $212.17, as analysts factor in more cautious assumptions around Medicare Advantage margins, earnings guidance, and recent sector wide target cuts following Q4 results and regulatory news. Analyst Commentary Recent research on Humana reflects a clear reset in expectations, with price targets moving lower and ratings clustered around neutral.
Aggiornamento della narrazione • Mar 07

HUM: Medicare Advantage Margin Recovery Will Drive Future Upside Potential

Our updated Humana fair value estimate moves from $287.38 to $223.88, reflecting analysts' lower price targets across the Street as they factor in uncertainty around Medicare Advantage margin improvement, EPS guidance drivers, and the profitability of recent membership growth. Analyst Commentary Recent Street research around Humana has turned more cautious, with multiple firms cutting price targets and some shifting to more neutral stances.
Aggiornamento della narrazione • Feb 21

HUM: Medicare Advantage Margin Uncertainty Will Drive A Prolonged Earnings Reset

Humana's analyst fair value estimate has been reset from about $199.74 to $146.00. This reflects a broad wave of lower price targets as analysts factor in updated EPS guidance, Medicare Advantage margin uncertainty, and recent model revisions after Q4 results and regulatory developments.
Aggiornamento della narrazione • Feb 07

HUM: Policy And Margin Headwinds Will Shape A Gradual Recovery Path

Narrative Update on Humana The analyst price target for Humana has been reduced by about $18.75. Analysts point to recent downgrades, cautious reactions to CMS rate developments, and more conservative margin assumptions, even as they acknowledge potential longer term sector recovery drivers.
Articolo di analisi • Feb 05

Humana Inc. (NYSE:HUM) Might Not Be As Mispriced As It Looks After Plunging 30%

Humana Inc. ( NYSE:HUM ) shareholders won't be pleased to see that the share price has had a very rough month, dropping...
Aggiornamento della narrazione • Jan 24

HUM: Margin And Policy Uncertainty Will Drive A More Cautious Outlook

Narrative Update Analysts have trimmed their price expectations for Humana, with the updated fair value estimate moving from about US$224 to roughly US$218. This reflects a higher discount rate, more cautious profit margin assumptions, and a lower future P/E multiple, even though modeled revenue growth is higher and recent research views are a mix of supportive and more restrained perspectives.
Aggiornamento della narrazione • Jan 08

HUM: Legal Appeals And Margin Recovery Prospects Will Shape Balanced Outlook

Humana's updated analyst price target has edged down by about $1 to roughly $287. Analysts are balancing slightly higher long term revenue and margin assumptions with mixed ratings that range from Sell to Outperform across recent research.
Articolo di analisi • Dec 19

Humana (NYSE:HUM) Is Paying Out A Dividend Of $0.885

Humana Inc. ( NYSE:HUM ) has announced that it will pay a dividend of $0.885 per share on the 30th of January. This...
Aggiornamento della narrazione • Dec 14

HUM: Legal Appeals And Star Ratings Will Shape Balanced Outlook Ahead

Analysts have modestly increased Humana's fair value estimate by about $2 to roughly $288, reflecting slightly stronger projected revenue growth and improved earnings visibility, even as they incorporate more conservative sector margin assumptions and ongoing concerns about Medicare Advantage and Medicaid cyclicality. Analyst Commentary Recent Street research paints a mixed picture for Humana, with modest upside to fair value supported by improving earnings visibility, but tempered by meaningful concerns around Medicare Advantage dynamics, contract diversification efforts, and broader managed care cyclicality.
Articolo di analisi • Dec 05

Humana (NYSE:HUM) Is Paying Out A Dividend Of $0.885

Humana Inc.'s ( NYSE:HUM ) investors are due to receive a payment of $0.885 per share on 30th of January. This payment...
Aggiornamento della narrazione • Nov 30

HUM: Shares Should Rebound As Legal Efforts Progress On Medicare Bonus Cuts

Humana's analyst price target has been modestly reduced from $288.46 to $286.63. Analysts are factoring in more conservative margin assumptions following recent quarterly results and updated evaluations of the company's revenue growth and profitability outlook.
Articolo di analisi • Nov 16

Humana (NYSE:HUM) Has Announced A Dividend Of $0.885

Humana Inc. ( NYSE:HUM ) has announced that it will pay a dividend of $0.885 per share on the 30th of January. This...
Aggiornamento della narrazione • Nov 15

HUM: Confidence Will Increase As Medicare Advantage Star Ratings Recover

Humana's analyst price target has been revised lower by approximately $7 to $288.46. Analysts cite a more cautious outlook on margins and an uneven recovery in Medicare Advantage profitability.
Articolo di analisi • Nov 13

Humana's (NYSE:HUM) Conservative Accounting Might Explain Soft Earnings

Investors were disappointed with the weak earnings posted by Humana Inc. ( NYSE:HUM ). However, our analysis suggests...
Articolo di analisi • Nov 02

Humana (NYSE:HUM) Will Pay A Dividend Of $0.885

The board of Humana Inc. ( NYSE:HUM ) has announced that it will pay a dividend on the 30th of January, with investors...
Aggiornamento della narrazione • Nov 01

HUM: Medicare Advantage Stars And ACA Premiums Will Shape Balanced Near-Term Outlook

Humana's analyst price target increased slightly, rising by approximately $0.83 to $295.38. Analysts cite mixed dynamics in Medicare Advantage star ratings and improving earnings visibility as factors supporting cautious optimism.
Aggiornamento della narrazione • Oct 18

AI, In-Home Visits, Medicaid And CenterWell Will Improve Care Delivery

Humana’s analyst price target increased slightly to $294.54 from $292.87. Analysts cite improved earnings visibility and the stability of Medicare Advantage star ratings as supporting factors for the upward revision.
Aggiornamento della narrazione • Oct 04

AI, In-Home Visits, Medicaid And CenterWell Will Improve Care Delivery

Humana's analyst price target has fallen from approximately $299 to $293 per share, as analysts cite ongoing challenges in Medicare Advantage star ratings and a more cautious growth outlook. This comes despite recent plan diversification efforts.
Aggiornamento della narrazione • Sep 05

AI, In-Home Visits, Medicaid And CenterWell Will Improve Care Delivery

Humana’s modestly higher fair value reflects improving investor sentiment, positive management commentary on future plan positioning, raised earnings guidance, and incremental legislative benefits, offset by some caution around interest rates and policy uncertainty, resulting in the consensus analyst price target rising slightly from $293.05 to $294.86. Analyst Commentary Improved investor sentiment and sector group valuations suggest estimates may have bottomed, with upcoming catalysts including government budget deals, Medicare Advantage and ACA pricing, and star ratings for future plans.
Articolo di analisi • Aug 26

Humana (NYSE:HUM) Has Affirmed Its Dividend Of $0.885

Humana Inc. ( NYSE:HUM ) will pay a dividend of $0.885 on the 31st of October. The dividend yield is 1.2% based on this...
Articolo di analisi • Aug 15

Humana Inc. (NYSE:HUM) Stocks Shoot Up 27% But Its P/E Still Looks Reasonable

NYSE:HUM 1 Year Share Price vs Fair Value Explore Humana's Fair Values from the Community and select yours Humana Inc...
Seeking Alpha • Feb 12

Humana Q4 Earnings Review: A Tough Quarter -- And A Rating Downgrade

Summary Humana Inc.'s Q4 and full-year 2024 earnings report shows a 10% revenue increase but significant losses, highlighting major structural issues in its business model. Rising healthcare utilization and insufficient CMS rate increases have severely impacted Humana's profitability, with shares down 50% from their 2023 peak. New management aims to improve efficiency and service quality, but the company's future hinges on CMS rate decisions and star-rating litigation outcomes. Given the high uncertainty and potential for further losses, I recommend a “Hold” on HUM shares unless willing to take substantial risk. Read the full article on Seeking Alpha
Seeking Alpha • Jan 10

Humana's Growth Vs. Rising Costs: Why It's A Hold For Cautious Investors

Summary Humana is doubling down on Medicare Advantage and healthcare services while cutting less profitable areas. Higher costs and lower profit margins are putting pressure on the business right now. Medicare Advantage growth and expanding healthcare services show long-term potential. Regulatory changes and restructuring costs could make the next couple of years bumpy. The stock looks fairly priced, so holding for now seems like the best move. Read the full article on Seeking Alpha
Seeking Alpha • Dec 18

Humana, Cigna Plunge On Trump's Latest Promise: A Potential Buying Opportunity?

Summary The healthcare industry, particularly PBMs, faces bipartisan scrutiny, leading to significant stock declines for Humana and Cigna, presenting a contrarian investment opportunity. President-elect Donald Trump's stance on PBMs and bipartisan legislative proposals signal potential regulatory changes, creating market uncertainty for PBM-affiliated companies. Despite recent financial setbacks, Cigna and Humana show strong revenue growth, with investment losses and rising benefit costs impacting short-term profitability. Given the current low valuations, I reaffirm both Humana and Cigna as 'buy' candidates, as potential regulatory impacts may already be priced in. Read the full article on Seeking Alpha

Previsioni di crescita degli utili e dei ricavi

NYSE:HUM - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/2028180,4602,7613,0723,33815
12/31/2027170,2831,7872,6032,50921
12/31/2026162,3269902,4212,58320
3/31/2026137,2001,1301,2721,844N/A
12/31/2025129,6641,188375921N/A
9/30/2025126,3621,2911,5472,045N/A
6/30/2025123,1101,5762,4392,932N/A
3/31/2025120,2621,7102,3812,874N/A
12/31/2024117,7611,2072,3912,966N/A
9/30/2024115,0101,359-4,344-3,640N/A
6/30/2024112,0361,711-5,054-4,246N/A
3/31/2024109,2431,991-3,241-2,283N/A
12/31/2023106,3742,4892,9773,981N/A
9/30/2023102,3513,0154,9925,988N/A
6/30/202398,7273,37812,13913,189N/A
3/31/202395,6423,1159,90710,972N/A
12/31/202292,8702,8063,4504,587N/A
9/30/202291,4852,8078,3859,618N/A
6/30/202290,5123,1432,7294,000N/A
3/31/202287,4953,0352,0803,401N/A
12/31/202183,0642,9339202,262N/A
9/30/202182,2012,6731,4002,641N/A
6/30/202180,4502,4824561,621N/A
3/31/202178,8883,7223,2664,328N/A
12/31/202077,1553,3674,6755,639N/A
9/30/202074,3884,1534,9705,868N/A
6/30/202070,5543,5025,6376,495N/A
3/31/202067,7162,6144,0734,862N/A
12/31/201964,8882,707N/A5,284N/A
9/30/201962,7612,550N/A4,439N/A
6/30/201960,7262,505N/A942N/A
3/31/201958,7401,758N/A-617N/A
12/31/201856,9121,683N/A2,173N/A
9/30/201855,9331,512N/A-405N/A
6/30/201855,0091,367N/A3,513N/A
3/31/201854,2841,824N/A3,532N/A
12/31/201753,7672,448N/A4,051N/A
9/30/201753,4561,863N/A4,189N/A
6/30/201753,8681,814N/A5,829N/A
3/31/201754,3411,475N/A5,639N/A
12/31/201654,379614N/A1,936N/A
9/30/201654,8621,116N/A5,046N/A
6/30/201654,531980N/A1,575N/A
3/31/201654,2561,100N/A1,263N/A
12/31/201554,2891,276N/A868N/A
9/30/201553,2561,320N/A724N/A
6/30/201552,1311,296N/A646N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di HUM ( 27% all'anno) è superiore al tasso di risparmio ( 3.5% ).

Guadagni vs Mercato: Si prevede che gli utili di HUM ( 27% all'anno) cresceranno più rapidamente del mercato US ( 18.5% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di HUM cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di HUM ( 8.1% all'anno) crescerà più lentamente rispetto al mercato US ( 12.7% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di HUM ( 8.1% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di HUM sarà basso tra 3 anni ( 11.6 %).

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/06/25 21:38
Prezzo dell'azione a fine giornata2026/06/25 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Humana Inc. è coperta da 37 analisti. 21 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
David ToungArgus Research Company
Hua HaBaird
Andrew MokBarclays